Results 71 to 80 of about 15,823 (164)

Tributyltin Protumorigenic Effects Targeting Prostate Cancer Cell Metabolism, Proliferation, Migration, and Invasion

open access: yesEnvironmental Toxicology, Volume 41, Issue 9, Page 709-729, September 2026.
ABSTRACT Prostate cancer (PCa) is an endocrine‐related cancer highly dependent on androgenic signaling. Beyond hormone dependence, extrinsic factors play a significant role in the risk of developing PCa, which raises concern about the influence of environmental compounds such as endocrine‐disrupting chemicals (EDCs). Tributyltin (TBT) is an EDC used in
Mariana Feijó   +9 more
wiley   +1 more source

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy

open access: yesBJU International, Volume 138, Issue 3, Page 430-437, September 2026.
Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 ...
Navid Roessler   +22 more
wiley   +1 more source

How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data

open access: yesCancer, Volume 132, Issue 16, 15 August 2026.
In a retrospective analysis of Veterans Health Administration data for patients with metastatic castration‐sensitive prostate cancer (mCSPC), achieving a prostate‐specific antigen (PSA) of <0.2 ng/mL (whether or not a PSA decline of 90% was reached) within 9 months of initiating androgen deprivation therapy (ADT) ± other treatments was associated with ...
Stephen J. Freedland   +7 more
wiley   +1 more source

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, Volume 13, Issue 46, 17 August 2026.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu   +15 more
wiley   +1 more source

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

open access: yesCancer Medicine, Volume 15, Issue 8, August 2026.
This review explores how AI and multimodal data fusion transform oncology through enhanced screening, precision diagnosis, and personalized therapy. By dissecting core challenges—including data bias and explainability—it provides a strategic framework for the digital transformation and ethical implementation of AI in clinical cancer care.
Yifeng Xie   +6 more
wiley   +1 more source

Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion

open access: yesCancer, Volume 132, Issue 15, 1 August 2026.
Abstract Background Vobramitamab duocarmazine is an investigational antibody–drug conjugate (ADC) targeting B7 homolog 3 (B7‐H3) with a cytotoxic duocarmycin‐based DNA‐alkylating payload. This study evaluated its safety and antitumor activity in advanced solid tumors.
Eugene Shenderov   +20 more
wiley   +1 more source

ROS‐ATM‐CBP axis‐mediated PARP1 lactylation aggravates doxorubicin‐induced cardiotoxicity

open access: yesClinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ROS function as signalling molecules to promote CBP‐mediated PARP1 lactylation in an ATM dependent manner, which induces PARP1 PARylation and ultimate cell apoptosis. CBP and SIRT1 as specific lactyltransferase and delactylase of PARP1. Lactylation of PARP1 depends on the LDHA activity and lactate production.
Wenbin Wang, Yingxian Sun
wiley   +1 more source

SLC7A5 promotes colorectal cancer liver metastasis by reprogramming tryptophan metabolism through the Kyn/XANA‒AhR axis and reshaping the immune microenvironment

open access: yesClinical and Translational Medicine, Volume 16, Issue 8, August 2026.
SLC7A5‒Kyn/XANA signalling activates AhR to drive EMT and metastatsis. SLC7A5 knockdown enhances macrophage antigen presentation and reverses CD8+ T‐cell exhaustion. SLC7A5 knockdown induces antigen‐driven and IgG‐secreting B‐cell clonal expansion. Combination of SLC7A5 inhibition and anti‐PD‐1 therapy offers clinical targeting.
Yaohao Luo   +8 more
wiley   +1 more source

The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy

open access: yesClinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Hypoxia, oncogenic signaling, transcriptional and epigenetic remodeling, and H. pylori–microbiota interactions drive the Warburg effect in gastric cancer. Enhanced glycolysis and lactate export support biosynthesis, remodel the tumor microenvironment, promote stromal activation and immune suppression, and reveal actionable biomarkers and therapeutic ...
Guanmo Liu   +7 more
wiley   +1 more source

Neutrophil‐based immunotherapy: A metabolic lens on mechanisms and therapeutic implications

open access: yesClinical and Translational Medicine, Volume 16, Issue 8, August 2026.
TAN metabolic reprogramming critically contributes to tumour immune evasion. A 4‑Tier TAN‑MetaC classification framework is proposed, along with an overview of translational opportunities and bottlenecks for TAN metabolism‑targeted immunotherapies. Abstract Background Tumor‐associated neutrophils (TANs) serve as pivotal immune modulators in the tumor ...
Wenchao Xu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy